Real-World Efficacy of Ustekinumab versus Vedolizumab for Ulcerative Colitis: Differences between Short- and Long-Term Outcomes Based on Endoscopic Remission
Inflammatory Intestinal Diseases · 05.05.2026 · 11 (1) · 250-259
DOI: 10.1159/000552373 ↗Kurz gefasst
Fachartikel in der Zeitschrift Inflammatory Intestinal Diseases, online erschienen am 05.05.2026. Verfasst von Makoto Furuya und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Ustekinumab (UST) and vedolizumab (VED) are effective for ulcerative colitis (UC), but long-term real-world data, particularly regarding endoscopic remission, remain limited.
Methods
Patients with UC who were treated with UST or VED at two tertiary centers were enrolled in this retrospective study. Baseline imbalances were adjusted using inverse probability of treatment weighting. The primary outcome was the endoscopic remission rates (Mayo Endoscopic Subscore [MES] 0 or 1 and MES 0 alone) at 1 year and 2 years. Secondary outcomes included clinical remission rates and treatment persistence.
Results
Overall, 197 patients were analyzed: 96 received UST, and 101 received VED. The median observation period was 2.5 years. Clinical remission rates did not differ between the two groups. Treatment persistence was higher with UST than with VED (HR: 1.85; 95% CI: 1.13–3.02; p = 0.014), particularly in the early period. At 1 year, there were no significant differences in endoscopic remission rates for MES 0 or 1 and MES 0 alone between the two groups. At 2 years, patients treated with UST were significantly more likely to achieve MES 0 or 1 (UST, 45.0% vs. VED, 19.8%; OR for VED vs. UST, 0.30; 95% CI: 0.11–0.82; p = 0.019), whereas achievement of MES 0 alone did not differ significantly.
Conclusion
UST was associated with a higher rate of achieving MES 0 or 1, while deep remission rates were comparable. This may explain a more pronounced difference in treatment persistence in the short-term phase, with the difference decreasing over time.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
- Department of Gastroenterology, IBD Center, Tsujinaka Hospital Kashiwanoha, Chiba, Japan.
- Endoscopy Center, Chiba University Hospital, Chiba, Japan.
Zitieren
APA
Furuya, M., Kato, J., Takeuchi, K., Shimizu, K., Ito, T., Shu, N., Ozeki, Y., Horio, R., Goto, C., Ishikawa, T., Oura, H., Kaneko, T., Ohta, Y., Taida, T., Okimoto, K., Saito, K., & Matsumura, T. (2026). Real-World Efficacy of Ustekinumab versus Vedolizumab for Ulcerative Colitis: Differences between Short- and Long-Term Outcomes Based on Endoscopic Remission. Inflammatory Intestinal Diseases, 11(1), 250-259. https://doi.org/10.1159/000552373
Vancouver
Furuya M, Kato J, Takeuchi K, Shimizu K, Ito T, Shu N, et al. Real-World Efficacy of Ustekinumab versus Vedolizumab for Ulcerative Colitis: Differences between Short- and Long-Term Outcomes Based on Endoscopic Remission. Inflammatory Intestinal Diseases. 2026;11(1):250-259. doi:10.1159/000552373
BibTeX
@article{Furuya2026,
author = {Furuya, Makoto and Kato, Jun and Takeuchi, Ken and Shimizu, Kento and Ito, Toshiyuki and Shu, Nobuaki and Ozeki, Yusuke and Horio, Ryosuke and Goto, Chihiro and Ishikawa, Tsubasa and Oura, Hirotaka and Kaneko, Tatsuya and Ohta, Yuki and Taida, Takashi and Okimoto, Kenichiro and Saito, Keiko and Matsumura, Tomoaki},
title = {Real-World Efficacy of Ustekinumab versus Vedolizumab for Ulcerative Colitis: Differences between Short- and Long-Term Outcomes Based on Endoscopic Remission},
journal = {Inflammatory Intestinal Diseases},
year = {2026},
volume = {11},
number = {1},
pages = {250--259},
doi = {10.1159/000552373}
}
EUVIMED